- News Home
12 December 2013 1:00 pm ,
Vol. 342 ,
Stefan Behnisch has won awards for designing science labs and other buildings that are smart, sustainable, and...
The iconic 125-year-old Lick Observatory on Mount Hamilton near San Jose, California, is facing the threat of closure...
Recent results from the Curiosity Mars rover have helped scientists formulate a plan for the next phase of its mission...
A new, remarkably powerful drug that cripples the hepatitis C virus (HCV) came to market last week, but it sells for $...
In pretoothbrush populations, gumlines would often be marred by a thick, visible crust of calcium phosphate, food...
Evolutionary biologists have long studied how the Mexican tetra, a drab fish that lives in rivers and creeks but has...
Victorian astronomers spent countless hours laboriously charting the positions of stars in the sky. Such sky mapping,...
In an ambitious project to study 1000 years of sickness and health, researchers are excavating the graveyard of the now...
- 12 December 2013 1:00 pm , Vol. 342 , #6164
- About Us
In Japan, Novartis Official Apologizes for Problematic Drug Trials, Promises Reforms
3 October 2013 1:15 pm
TOKYO—After a deep ritual bow while cameras clicked and flashed, David Epstein, division head of Novartis Pharmaceuticals, apologized for "the great concern and inconvenience experienced by patients, their families, and health care practitioners" as a result of flawed Japanese clinical trials involving one of the company’s drugs. Novartis employees participated in the trials of the hypertension drug Diovan, but the potential conflict was not reported by researchers. And a ministry of health panel reported earlier this week that there was data manipulation in scientific reports resulting from the trials, but could not conclude who did it or why.
Diovan, known generically as valsartan, was approved to treat hypertension in Japan in 2000. Later clinical trials conducted at several universities sought to study whether the drug also helped prevent heart disease and stroke. Investigators found that a former Novartis employee helped two university research teams with data analysis, though that person's link to the company was not disclosed in published papers.
The various investigations have indicated that the university researchers turned to Novartis employees for help in the statistical analysis. "In retrospect, people did not have the skills in academia to conduct these trials, nor did we have the controls in place to ensure our people participated in an appropriate manner," Epstein said. He said that he agreed with the interim finding of the health ministry panel that both Novartis and the universities involved shared blame.
"We will correct what has been done and make sure it doesn't happen again," Epstein said, explaining that the company has already taken corrective steps. He said the fact that the studies were controversial at the time they were published should have gotten more attention from the company. Their countermeasures include making sure that, in the future, published data are complete and proper.
Regarding ongoing probes, including the possibility that the company violated drug marketing laws, Epstein said: "We are committed to cooperate with any government investigation."